View Exam | PowerPak

1. Which MDR organism is the cause of most antibiotic-resistant deaths?

A. CRE B. ESBL C. MRSA D. VRE

2. Multi-drug resistant P. aeruginosa, ESBL-producing Enterobacteriaceae, CRE, VRE are associated with which type of infection?

A. Endovascular B. Post-neurosurgical CNS C. Skin and soft tissue D. Urinary tract

3. By what mechanism does resistance develop in the fluoroquinolones?

A. Efflux pumps B. Porin channel loss C. Ribosomal mutations D. Target site mutations

4. Changes in cell surface adaption leads to resistance to which antibiotics?

A. Daptomycin, vancomyin B. Linezolid, ceftaroline C. Penicillin, ampicillin D. Tetracyclines

5. What resistance mechanism prevents polymyxin antibiotics from binding to their target site of action?

A. Cell surface changes B. Mutations in the lipopolysaccharide C. Ribosomal mutations D. Target site mutations

6. How does relebactam work in the combination agent imipenem/cilastatin/relebactam?

A. Binds to extracellular free iron B. Overcomes efflux pump resistance C. Prevents transfer RNA binding D. Restores activity of imipenem against MDR GNB

7. Which recently approved antibiotic is recommended as an alternative treatment for CRE and MDR-Pa infections?

A. Cefiderocol B. Eravacycline C. Imipenem/cilastatin/relebactam D. Lefamulin E. Omadacycline F. Plazomicin

8. Which recently approved antibiotic is recommended as a first-line option for CRE and MDR-Pa infections?

A. Cefiderocol B. Eravacycline C. Imipenem/cilastatin/relebactam D. Lefamulin E. Omadacycline F. Plazomicin

9. Which aspect of the core components of an antimicrobial stewardship program are especially well-suited for pharmacist oversight?

A. Antibiotic timeouts B. Facility antibiogram C. NHSN AUR reports D. Prospective audit

10. Bacterial co-infections occur in most patients hospitalized with COVID-19.

A. True B. False

11. What antibiotic would you empirically start as you await the final blood and urine culture results? CASE STUDY

A. Piperacillin-tazobactam B. Meropenem C. Ceftazidime-avibactam D. Fosfomycin E. Nitrofurantoin

12. Which antibiotic agent would you avoid? CASE STUDY

A. Vancomycin B. Ceftaroline C. Daptomycin D. Linezolid

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which MDR organism is the cause of most antibiotic-resistant deaths?

2. Multi-drug resistant P. aeruginosa, ESBL-producing Enterobacteriaceae, CRE, VRE are associated with which type of infection?

3. By what mechanism does resistance develop in the fluoroquinolones?

4. Changes in cell surface adaption leads to resistance to which antibiotics?

5. What resistance mechanism prevents polymyxin antibiotics from binding to their target site of action?

6. How does relebactam work in the combination agent imipenem/cilastatin/relebactam?

7. Which recently approved antibiotic is recommended as an alternative treatment for CRE and MDR-Pa infections?

8. Which recently approved antibiotic is recommended as a first-line option for CRE and MDR-Pa infections?

9. Which aspect of the core components of an antimicrobial stewardship program are especially well-suited for pharmacist oversight?

10. Bacterial co-infections occur in most patients hospitalized with COVID-19.

11. What antibiotic would you empirically start as you await the final blood and urine culture results? CASE STUDY

12. Which antibiotic agent would you avoid? CASE STUDY

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which MDR organism is the cause of most antibiotic-resistant deaths?

2. Multi-drug resistant P. aeruginosa, ESBL-producing Enterobacteriaceae, CRE, VRE are associated with which type of infection?

3. By what mechanism does resistance develop in the fluoroquinolones?

4. Changes in cell surface adaption leads to resistance to which antibiotics?

5. What resistance mechanism prevents polymyxin antibiotics from binding to their target site of action?

6. How does relebactam work in the combination agent imipenem/cilastatin/relebactam?

7. Which recently approved antibiotic is recommended as an alternative treatment for CRE and MDR-Pa infections?

8. Which recently approved antibiotic is recommended as a first-line option for CRE and MDR-Pa infections?

9. Which aspect of the core components of an antimicrobial stewardship program are especially well-suited for pharmacist oversight?

10. Bacterial co-infections occur in most patients hospitalized with COVID-19.

11. What antibiotic would you empirically start as you await the final blood and urine culture results? CASE STUDY

12. Which antibiotic agent would you avoid? CASE STUDY

« Return to Activity

Customers who Purchased
this Activity also Purchased